Autologous dendritic cell immunotherapy (APAC Biotech)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAutologous dendritic cell immunotherapy (APAC Biotech)
Drug Alias NameAPCEDEN-OAPCEDEN for RCCAPCEDEN-CRAPCEDEN-LAPCEDEN-P +[6] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsProstatic NeoplasmsCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[4] 
Global Approved IndicationsProstatic NeoplasmsCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[4] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2017/04/01
Country/TerritoryIndia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesApac Biotech
China Registration ClassN/A

Develop Information

Active CompaniesApac Biotech
Inactive CompaniesN/A
Active IndicationsProstatic NeoplasmsCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeV03AX
Related LinksN/A